Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer

被引:0
|
作者
Noel Pabalan
Ofelia Francisco-Pabalan
Lillian Sung
Hamdi Jarjanazi
Hilmi Ozcelik
机构
[1] Saint Louis University,College of Natural Sciences
[2] University Health Network,Analytical Genetics Technology Centre, Princess Margaret Hospital
[3] Hospital for Sick Children,Division of Hematology/Oncology
[4] Ontario Ministry of the Environment,Environmental Monitoring and Reporting Branch
[5] Mount Sinai Hospital,Fred A. Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute
来源
Breast Cancer Research and Treatment | 2010年 / 124卷
关键词
Breast cancer; ERCC2; XPD; Asp312Asn; Lys751Gln; Adducts;
D O I
暂无
中图分类号
学科分类号
摘要
The excision repair cross-complementing group 2 gene (ERCC2) plays a key role in DNA repair. Several polymorphisms in the ERCC2 gene have been described, including the commonly occurring Lys751Gln and Asp312Asn polymorphisms. Studies investigating the association of these polymorphisms with breast cancer risk produced controversial results. To evaluate these associations presented in diverse populations, we have conducted a meta-analysis based on 40 studies from 33 publications in PubMed which included analyses of Lys751Gln (14,545 cases, 15,352 controls) and Asp312Asn polymorphisms (16,254 cases, 14,006 controls). Overall findings of both polymorphisms have implicated null effects (OR = 1.01–1.03) when the analyses were limited to the statistically powerful (≥80%) studies. Although modestly increased statistically significant breast cancer risk was detected in the underpowered studies (≤80%), removal of outliers resulted in null associations. Ethnic stratification showed non-significant and relatively null associations for both polymorphisms with breast cancer risk for the overall Caucasians as well as North American and the European sub-populations. Although statistically increased and decreased risks were observed for the homogenous populations of African-Americans (Lys751Gln, OR 1.25, 95% CI 1.03–1.53, P = 0.03) and Asians (Asp312Asn, ORs: 0.53–0.55, P values: 0.02–0.03), respectively, this may be the result of small sample size. Analyses of the homogeneous adduct studies, with relatively large sample size, exhibited increased risk for Lys751Gln (OR 1.20, 95% CI (1.02–1.41), P = 0.03) and Asp312Asn (OR 1.17 95% CI 1.02–1.34, P = 0.03) under the dominant genetic model. In conclusion, our results suggest null associations of both polymorphisms in the overall and the Caucasian subgroups, although some effects can be suggested for relatively smaller minority studies. Increased risk effect was more visible when the adduct studies are considered, suggesting the role of these polymorphisms in the presence of exposure to DNA damaging agents.
引用
收藏
页码:531 / 541
页数:10
相关论文
共 50 条
  • [41] The XPD Lys751Gln Polymorphism has Predictive Value in Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy: a Systemic Review and Meta-analysis
    Qian, Ying-Ying
    Liu, Xin-You
    Pei, Dong
    Xu, Jia-Li
    Shen, Hua
    Chen, Xiao-Feng
    Liu, Yi-Qian
    Shen, Li-Zong
    Shu, Yong-Qian
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (22) : 9699 - 9706
  • [42] The DNA repair gene XPD/ERCC2 polymorphisms Arg156Arg (exon 6) and Lys751 Gln (exon 23) are closely associated
    Topinka, Jan
    Hertz-Picciotto, Irva
    Dostal, Miroslav
    Chvatalova, Irena
    Yap, Poh-Sin
    Herr, Caroline E. W.
    Greenfield, Teri
    Sram, Radirn J.
    TOXICOLOGY LETTERS, 2007, 172 (1-2) : 85 - 89
  • [43] Associations between XPD polymorphisms and risk of breast cancer: a meta-analysis
    Jiang, Zheng
    Li, Chunxiang
    Xu, Ye
    Cai, Sanjun
    Wang, Xishan
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 123 (01) : 203 - 212
  • [44] RETRACTED: Comprehensive assessment of the association of ERCC2 Lys751Gln polymorphism with susceptibility to cutaneous melanoma (Retracted article. See April, 2017)
    Dong, Yuhao
    Zhuang, Le
    Ma, Weiyuan
    TUMOR BIOLOGY, 2013, 34 (02) : 1155 - 1160
  • [45] Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India
    Leelakumari Sreeja
    Volga S. Syamala
    Vani Syamala
    Sreedharan Hariharan
    Praveenkumar B. Raveendran
    R. V. Vijayalekshmi
    Jayaprakash Madhavan
    Ravindran Ankathil
    Journal of Cancer Research and Clinical Oncology, 2008, 134 : 645 - 652
  • [46] Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India
    Sreeja, Leelakumari
    Syamala, Volga S.
    Syamala, Vani
    Hariharan, Sreedharan
    Raveendran, Praveenkumar B.
    Vijayalekshmi, R. V.
    Madhavan, Jayaprakash
    Ankathil, Ravindran
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008, 134 (06) : 645 - 652
  • [47] Association between XPD Lys751Gln polymorphism and bladder cancer susceptibility: an updated and cumulative meta-analysis based on 6,836 cases and 8,251 controls
    Li, Sheng
    Zeng, Xian Tao
    Ruan, Xiao Lan
    Liu, Tong Zu
    Wang, Xing Huan
    MOLECULAR BIOLOGY REPORTS, 2014, 41 (06) : 3621 - 3629
  • [48] Association between XPD Lys751Gln polymorphism and bladder cancer susceptibility: an updated and cumulative meta-analysis based on 6,836 cases and 8,251 controls
    Sheng Li
    Xian Tao Zeng
    Xiao Lan Ruan
    Tong Zu Liu
    Xing Huan Wang
    Molecular Biology Reports, 2014, 41 : 3621 - 3629
  • [49] ERCC2 Lys751Gln rs13181 and XRCC2 Arg188His rs3218536 gene polymorphisms contribute to susceptibility of colon, gastric, liver, lung and prostate cancer
    Balkan, Eda
    Bilici, Mehmet
    Gundogdu, Betul
    Aksungur, Nurhak
    Kara, Asli
    Yasarl, Ezgi
    Dogan, Hasan
    Ozturk, Gurkan
    JOURNAL OF BUON, 2020, 25 (01): : 574 - 581
  • [50] Association Between ERCC2 Polymorphisms and Glioma Risk: a Meta-analysis
    Huang, Li-Ming
    Shi, Xi
    Yan, Dan-Fang
    Zheng, Min
    Deng, Yu-Jie
    Zeng, Wu-Cha
    Liu, Chen
    Lin, Xue-De
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (11) : 4417 - 4422